Cofrogliptin

CAS No. 1844874-26-5

Cofrogliptin( —— )

Catalog No. M35685 CAS No. 1844874-26-5

Cofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 178 Get Quote
5MG 275 Get Quote
10MG 440 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cofrogliptin
  • Note
    Research use only, not for human use.
  • Brief Description
    Cofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).
  • Description
    Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
  • In Vitro
    Cofrogliptin (HSK7653) (compound 2) has the DPP-4 inhibitory activity with an IC50 value of 4.18 nM.
  • In Vivo
    Cofrogliptin (HSK7653) (compound 2) (IV: 0.5 mg/kg; PO: 2 mg/kg) exhibits extremely long half-lives and low rate of reduction of drug concentration after orally administration.Cofrogliptin (compound 2) (Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg) increases of half-lives, has high oral exposure, low i.v. clearance and hepatic microsomal clearance after intravenous dosing. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) exhibits longe inhibition time of DPP-4 and decreases HbA1c level at the doses of 3 and 10 mg/kg in ob/ob mice. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) also has a great potential of biweekly regimen for T2DM as indicated in rhesus monkeys.Animal Model:ob/ob mice Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg Result:Exhibited strong inhibition capability of plasma DPP-4 in a dose dependent manner. Animal Model:rhesus monkeys Dosage:10 mg/kg Administration:Single, orally, 10 mg/kg Result: Possessed the capability of plasma DPP-4 inhibition over 80% for at least 12 days.Remained the plasma DPP-4 inhibition rates of 76.16% and 43.41%, respectively at the end of second week and third week after administration.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    DPP
  • Recptor
    DPP-4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1844874-26-5
  • Formula Weight
    466.43
  • Molecular Formula
    C18H19F5N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (214.39 mM; Ultrasonic )
  • SMILES
    C(F)(F)(F)[C@@H]1[C@@H](C[C@H](N)[C@H](O1)C2=C(F)C=CC(F)=C2)N3CC=4C(C3)=NN(S(C)(=O)=O)C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. International NonproprietaryNames for PharmaceuticalSubstances (INN)
molnova catalog
related products
  • AZD-7986

    AZD-7986(INS-1007, AZD7986) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4.

  • Saikogenin A

    Saikogenin A is a dipeptidyl peptidase-4 inhibitor.

  • Denagliptin

    Denagliptin is a small molecule dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of endocrine ü metabolic diseases and can be used in the study of type 2 diabetes.